A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. (MONALEESA 7)

lain Information	
Primary registry identifying number	Protocol number
LBCTR2019020194	CLEE011E2301
MOH registration number	
9878 <i>-ص</i> /A	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Retrospective	LCTR was recently initiated, original file was previously submitted by Paper
Date of registration in national regulatory agency 10/11/2014	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
13/03/2021	10/11/2014
Public title	Acronym
A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. (MONALEESA 7)	MONALEESA 7
Scientific title	Acronym
A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer.	
Brief summary of the study: English	
This is a multi-center, randomized, double-blinded, placebo controlled trial in pre-menopausal women with advanced breast cancer.	
The purpose of this study is to assess the efficacy of LEE011, as measured by progression free survival (PFS), in premenopausal women with HR positive, HER2 negative advanced breast cancer	

 \sim

4410010005 00.40.40

Brief summary of the study: Arabic

أو الدواء الوهمي بالتزامن مع التاموكسيفن LEE011 دراسة عشوانية مزدوجة التعمية ومضبّطة بدواء وهميّ في المرحلة الثالثة حول دواء والغوزيريلين أو مثبّط أروماتيز غير ستيرويدي والغوزيريلين لعلاج النساء قبل انقطاع الطمث المصابات بسرطان الثدي المتقدّم الإيجابيّ والغوزيريلين أو مثبّط أروماتيز غير ستيرويدي والغوزيريلين لعلاج النساء قبل انقطاع الطمث المصابات بسرطان الثدي المتقدّم الإيجابيّ

Health conditions/problem studied: Specify

Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Interventions: Specify

•Drug: LEE011 LEE011 600 mg daily oral

•Drug: Tamoxifen tamoxifen 20 mg daily oral

•Drug: Letrozole letrozole 2.5 mg daily oral

•Drug: Anastrozole anastrozole 1 mg daily oral

•Drug: Goserelin Goserelin 3.6 mg subcutaneous injection

•Drug: LEE011 Placebo LEE011 placebo 600 mg daily oral

Key inclusion and exclusion criteria: Inclusion criteria

Inclusion Criteria:

•Patient has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy

•Patient is premenopausal or perimenopausal at the time of study entry

•Patients who received (neo) adjuvant therapy for breast cancer are eligible

•Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer

59

•Patient has HER2-negative breast cancer

Patient must have either measurable disease or If no measurable disease is present, then at least one predominantly lytic bone lesion
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Patient has adequate bone marrow and organ function

Key inclusion and exclusion criteria: Gender

Female

Key inclusion and exclusion criteria: Age minimum

18

Key inclusion and exclusion criteria: Exclusion criteria

Exclusion Criteria:

•Patient who has received a prior CDK4/6 inhibitor

Patient is postmenopausal

•Patients who currently have inflammatory breast cancer at screening.

•Patients who received any prior hormonal anti-cancer therapy for advanced breast cancer, except for ≤ 14 days of tamoxifen or NSAI ± goserelin for advanced breast cancer prior to randomization.

•Patient has a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal cell skin carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.

•Patient with CNS metastases.

•Patient has active cardiac disease or a history of cardiac dysfunction

•Patient is currently using other antineoplastic agents

•Patient is pregnant or nursing or physiologically capable of becoming pregnant and not using highly effective contraception

Other protocol-defined Inclusion/Exclusion may apply.

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type N/A

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age maximum

Trial scope	Trial scope: Specify scope	
Therapy	N/A	
Study design: Allocation	Study design: Masking	
Randomized controlled trial	Blinded (masking used)	
Study design: Control	Study phase	
Placebo	3	
Study design: Purpose	Study design: Specify purpose	
Treatment	N/A	
Study design: Assignment	Study design: Specify assignme	ent
Parallel	N/A	
IMP has market authorization	IMP has market authorization: S	pecify
Yes, Lebanon and Worldwide	Worldwide	
Name of IMP	Year of authorization	Month of authorization
LEE011 (Kisqali)	2017	7
Type of IMP		
Others		
Pharmaceutical class		
inhibitor of CDK4/6		
Therapeutic indication		
Hormone Receptor positive, HER 2 negative breast cancer. LEE011 is an eff in a variety of pRb-positive human neoplasms, especially in those that contai pathway.		
Therapeutic benefit		
Progression free survival		
Study model	Study model: Explain model	
N/A	N/A	
Study model: Specify model		
N/A		
Time perspective	Time perspective: Explain time	perspective
N/A	N/A	
Time perspective: Specify perspective		
N/A		
Target follow-up duration	Target follow-up duration: Unit	
Number of groups/cohorts		
Biospecimen retention	Biospecimen description	



Lebanon Clinical Trials Registry

Samples with DNA**	Samples are being sent to Q2 solutions central laboratory , this include as well safety labs for Hematology , biochemistry, urinalysis , in addition to circulating tumor DNA samples
Target sample size 28	Actual enrollment target size 28
Date of first enrollment: Type Actual	Date of first enrollment: Date 18/11/2014
Date of study closure: Type Actual	Date of study closure: Date 26/02/2021
Recruitment status Complete	Recruitment status: Specify
Date of completion 12/01/2016	
IPD sharing statement plan	IPD sharing statement description
No	Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
Additional data URL	This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
https://clinicaltrials.gov/ct2/show/record/NCT02278120?term=CLEE011E23	01&rank=1
Admin comments	

Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinical Trials.gov	NCT02278120	

Sources of Monetary or Material Support

Name

Novartis Pharma Services Inc.



Secondary Sponsors

Name

NA

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Fadi Farhat	Saida	Lebanon	+9613753 155	drfadi.trials@gm ail.com	Hammoud Hospital
Scientific	Hind Khairallah	Sin el fil	Lebanon	+961 1512002 #271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Nagi El Saghir	Beirut	Lebanon	+96113500 00 #7977	ns23@aub.edu.l b	American University Of Beirut Medical Center
Public	Marwan Ghosn	Beirut	Lebanon	00961 1613395	marwanghosnmd @yahoo.com	Hotel Dieu De France
Public	Dany Abi Gerges	Beirut	Lebanon	+9613341 960	abgerges@idm.n et.lb	Bellevue Medical Center
Public	Joseph Makdessi	Ashrafieh	Lebanon	+9613585 999	josejoce@yahoo. fr	Saint Georges Hospital University Medical Center
Public	Jawad Makarem	Al Chouf	Lebanon	+9613484 288	jawad.makarem @awmedicalvilla ge.org	Ain Wazein Medical Village

Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hammoud Hospital University Medical Center	Fadi Farhat	Hematology Oncology	Approved
American University of Beirut Medical Center	Nagi El Saghir	Hematology Oncology	Approved
Hotel Dieu De France	Marwan Ghosn	Hematology Oncology	Approved
Bellevue Medical Center	Dany Abi Gerges	Hematology Oncology	Approved
Saint Georges Hospital UNiversity Medical Center	Joseph Makdessi	Hematology Oncology	Approved
Ain Wazein Medical Village	Jawad Makarem	Hematology Oncology	Approved






REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Ethics Review				
Ethics approval obtained Approval date Contact name Contact name		Contact email	Contact phone	
American University of Beirut Medical Center	26/02/2015	Fuad Ziyadeh	fz05@aub.edu.lb	+961 (0) 1 350 000 ext:5445
Hotel Dieu de France	05/11/2014	Sami Richa	cue@usj.edu.lb	961421229
Saint George Hospital University Medical Center	29/01/2015	Michel Daher	mndaher@stgeorgehospital.org	+961 (0)1 441 733
Bellevue Medical Center	28/10/2014	Ghassan Maalouf	gmaalouf@bmc.com.lb	+961 (0) 1 682666 ext 5006
Ain w Zein Medical Village	29/05/2015	Hayat Kamaleddine	irb@awmedicalvillage.org	+961 (0) 5 509 001 ext 2014
Hammoud Hospital University Medical Center	21/10/2014	Ahmad Zaatari	zaatari@hammoudhospital.com	+961 (0) 7 723111 ext 1160



Countries of Recruitment
Name
Lebanon
Australia
Belgium
Brazil
Bulgaria
Canada
Colombia
France
Germany
Greece
Hungary
Italy
India
Malaysia
Mexico
Poland
Portugal
Saudi Arabia
Spain
Switzerland
Turkey
United Arab Emirates
United States of America



	Health Conditions or Problems Studied			
Condition Code		Keyword		
	breast cancer	Breast, unspecified (C50.9)	Premenaupausal advanced breast cancer	

Interventions		
Intervention	Description	Keyword
Informed consent, questionnaires, Lab tests, drug administration, radiology	Informed consent / patient history / drug administration / Lab tests	ICF, IMP, Lab tests and ECG , diary completion

Primary Outcomes		
Name	Time Points	Measure
Progression Free Survival	25 months	25 months

Key Secondary Outcomes		
Name	Time Points	Measure
Overall survival	69 Months	up to 69 Months
Safety and Tolerability of LEE011	26 Months	26 Months



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results **Results URL link Baseline characteristics** Participant flow Adverse events **Outcome measures** URL to protocol files